TWI622595B - 充當抗癌劑的經取代核苷衍生物 - Google Patents
充當抗癌劑的經取代核苷衍生物 Download PDFInfo
- Publication number
- TWI622595B TWI622595B TW105104968A TW105104968A TWI622595B TW I622595 B TWI622595 B TW I622595B TW 105104968 A TW105104968 A TW 105104968A TW 105104968 A TW105104968 A TW 105104968A TW I622595 B TWI622595 B TW I622595B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- mmol
- compound
- methyl
- etoac
- Prior art date
Links
- AQGOZRKFBKEVFZ-ZHALLVOQSA-N CCOCc1n[nH]c(C[C@H]([C@H]([C@H]([n]2c3ncnc(C)c3cc2)[O]=C=C)O)O)c1 Chemical compound CCOCc1n[nH]c(C[C@H]([C@H]([C@H]([n]2c3ncnc(C)c3cc2)[O]=C=C)O)O)c1 AQGOZRKFBKEVFZ-ZHALLVOQSA-N 0.000 description 1
- DJUZHNZMVHIRPJ-ZGAAAFHUSA-N C[C@@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c(ncnc2N)c2nc1)O Chemical compound C[C@@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c(ncnc2N)c2nc1)O DJUZHNZMVHIRPJ-ZGAAAFHUSA-N 0.000 description 1
- ZBUYPOCFIPAVOZ-WXXHYUIPSA-N C[C@H]([C@H]([C@H]([C@H]([n]1c2ncnc(C)c2cc1)O)O)O)[C@H](c1ccccc1)O Chemical compound C[C@H]([C@H]([C@H]([C@H]([n]1c2ncnc(C)c2cc1)O)O)O)[C@H](c1ccccc1)O ZBUYPOCFIPAVOZ-WXXHYUIPSA-N 0.000 description 1
- DJUZHNZMVHIRPJ-RWONEVQGSA-N C[C@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(N)c2nc1)O Chemical compound C[C@H]([C@H]([C@H]([C@H]1O)O)O[C@H]1[n]1c2ncnc(N)c2nc1)O DJUZHNZMVHIRPJ-RWONEVQGSA-N 0.000 description 1
- GNLMRHGPHSVOJQ-QSJFSLAZSA-N Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(c(cc3)ccc3F)(F)F)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@@H]3C(c(cc3)ccc3F)(F)F)c2ncn1 GNLMRHGPHSVOJQ-QSJFSLAZSA-N 0.000 description 1
- VVNQYJYZOIRSRC-HLNWXESRSA-N Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@H]3c(cc3)n[n]3-c3ccccc3)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]([C@@H]3O)O)O[C@H]3c(cc3)n[n]3-c3ccccc3)c2ncn1 VVNQYJYZOIRSRC-HLNWXESRSA-N 0.000 description 1
- XREICMJCVZYTAR-CGKSDVGLSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)OC(C(c4cc(F)cc(C(F)(F)F)c4)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)OC(C(c4cc(F)cc(C(F)(F)F)c4)O)[C@H]3O)c2ncn1 XREICMJCVZYTAR-CGKSDVGLSA-N 0.000 description 1
- RASMCBDASZAHRP-RIUYPTKQSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 RASMCBDASZAHRP-RIUYPTKQSA-N 0.000 description 1
- CJOLNWSXRHCRGA-RIUYPTKQSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c4ccccc4)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@@H](c4ccccc4)O)[C@H]3O)c2ncn1 CJOLNWSXRHCRGA-RIUYPTKQSA-N 0.000 description 1
- RASMCBDASZAHRP-RNGZQALNSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@@H]([C@H](c(cc4)ccc4F)O)[C@H]3O)c2ncn1 RASMCBDASZAHRP-RNGZQALNSA-N 0.000 description 1
- JJSRCFYJJKHXSP-FSNPWBFUSA-N Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@H]([C@@H](c4cc(N(C)C)ncc4)O)[C@H]3O)c2ncn1 Chemical compound Cc1c(cc[n]2[C@@H]([C@@H]3O)O[C@H]([C@@H](c4cc(N(C)C)ncc4)O)[C@H]3O)c2ncn1 JJSRCFYJJKHXSP-FSNPWBFUSA-N 0.000 description 1
- DQMAAYMQZKAQJY-FSNPWBFUSA-N Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2[n](C(F)F)cn3)O)[C@H]1O Chemical compound Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2[n](C(F)F)cn3)O)[C@H]1O DQMAAYMQZKAQJY-FSNPWBFUSA-N 0.000 description 1
- LOOUVRBRGOENGZ-FSNPWBFUSA-N Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2nc[n]3C(F)F)O)[C@H]1O Chemical compound Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c(cc2)cc3c2nc[n]3C(F)F)O)[C@H]1O LOOUVRBRGOENGZ-FSNPWBFUSA-N 0.000 description 1
- WNGZPIOXKRMXPJ-ORDFZIBCSA-N Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c2cccc(C(F)(F)F)c2)O)[C@H]1O Chemical compound Cc1ncnc2c1cc[n]2[C@@H]([C@@H]1O)O[C@H]([C@@H](c2cccc(C(F)(F)F)c2)O)[C@H]1O WNGZPIOXKRMXPJ-ORDFZIBCSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119932P | 2015-02-24 | 2015-02-24 | |
| US62/119,932 | 2015-02-24 | ||
| US201562213801P | 2015-09-03 | 2015-09-03 | |
| US62/213,801 | 2015-09-03 | ||
| US201662279209P | 2016-01-15 | 2016-01-15 | |
| US62/279,209 | 2016-01-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201643176A TW201643176A (zh) | 2016-12-16 |
| TWI622595B true TWI622595B (zh) | 2018-05-01 |
Family
ID=55451515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105104968A TWI622595B (zh) | 2015-02-24 | 2016-02-19 | 充當抗癌劑的經取代核苷衍生物 |
Country Status (29)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| ES2891320T3 (es) | 2016-03-10 | 2022-01-27 | Janssen Pharmaceutica Nv | Análogos de nucleósidos sustituidos para su uso como inhibidores de PRMT5 |
| KR20180116307A (ko) | 2016-03-10 | 2018-10-24 | 얀센 파마슈티카 엔.브이. | Prmt5 저해제로 사용하기 위한 치환 뉴클레오사이드 유사체 |
| CA3033020A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| MX392051B (es) | 2016-09-14 | 2025-03-21 | Janssen Pharmaceutica Nv | Inhibidores espirobiciclicos de la interaccion de menina-mll |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| WO2018065365A1 (en) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| KR102531344B1 (ko) * | 2016-10-03 | 2023-05-10 | 얀센 파마슈티카 엔.브이. | Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체 |
| JP7142010B2 (ja) | 2016-12-15 | 2022-09-26 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のアゼパン阻害剤 |
| WO2018152501A1 (en) * | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11220524B2 (en) * | 2017-02-20 | 2022-01-11 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
| WO2018160855A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| BR112020002736A2 (pt) | 2017-08-09 | 2020-07-28 | Prelude Therapeutics, Incorporated | inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) |
| CA3079545A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| JP7352544B2 (ja) | 2017-12-08 | 2023-09-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 新規なスピロ二環式類似体 |
| AU2018385664B2 (en) | 2017-12-13 | 2022-06-02 | Lupin Limited | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CA3092357A1 (en) * | 2018-03-14 | 2019-09-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| US20210309687A1 (en) * | 2018-08-07 | 2021-10-07 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US20220160713A1 (en) * | 2019-02-13 | 2022-05-26 | Prelude Therapeutics, Incorporated | Selective inhibitor of protein arginine methyltransferase 5 (prmt5) |
| JP7609798B2 (ja) * | 2019-03-25 | 2025-01-07 | カリフォルニア インスティチュート オブ テクノロジー | Ｐｒｍｔ５インヒビター及びその使用 |
| WO2020206299A1 (en) | 2019-04-05 | 2020-10-08 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| DK3980417T3 (en) | 2019-06-10 | 2023-12-18 | Lupin Ltd | PRMT5-Inhibitorer |
| PE20220433A1 (es) | 2019-06-12 | 2022-03-29 | Janssen Pharmaceutica Nv | Intermedios espirobiciclicos novedosos |
| RS64931B9 (sr) | 2019-06-18 | 2025-06-30 | Pfizer | Derivati benzizoxazol sulfonamida |
| BR112022004630A2 (pt) * | 2019-09-18 | 2022-05-31 | Prelude Therapeutics Inc | Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) |
| BR112022007808A2 (pt) | 2019-10-22 | 2022-07-05 | Lupin Ltd | Combinação farmacêutica de inibidores de prmt5 |
| JP7664248B2 (ja) | 2019-12-03 | 2025-04-17 | ルピン・リミテッド | Ｐｒｍｔ５阻害剤としての置換ヌクレオシドアナログ |
| UA129208C2 (uk) | 2019-12-19 | 2025-02-05 | Янссен Фармацевтика Нв | Заміщені спіропохідні з прямим ланцюгом |
| CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| KR20230096973A (ko) | 2020-08-18 | 2023-06-30 | 인사이트 코포레이션 | Jak 저해제를 제조하기 위한 방법 및 중간체 |
| US20240101589A1 (en) * | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
| WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| WO2023017152A1 (en) * | 2021-08-13 | 2023-02-16 | Albert-Ludwigs-Universität Freiburg | Specific small molecule inhibitors that block kmt9 methyltransferase activity and function |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492348B1 (en) * | 1998-06-23 | 2002-12-10 | Smithkline Beecham Corporation | Adenosine derivatives |
| US20040043960A1 (en) * | 2002-08-15 | 2004-03-04 | Jeff Zablocki | Partial and full agonists of A1 adenosine receptors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795977A (en) * | 1989-09-15 | 1998-08-18 | Metabasis Therapeutics, Inc. | Water soluble adenosine kinase inhibitors |
| US5864033A (en) * | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6831069B2 (en) * | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| EP2408306A4 (en) * | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| EP2731434A4 (en) * | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
| US8575119B2 (en) * | 2011-09-23 | 2013-11-05 | Enanta Pharmaceuticals, Inc. | 2′-chloroacetylenyl substituted nucleoside derivatives |
| WO2015200680A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AR104326A1 (es) * | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| JP2018523665A (ja) * | 2015-08-06 | 2018-08-23 | キメリックス インコーポレイテッド | 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 |
-
2016
- 2016-02-15 CN CN201680011823.1A patent/CN107278205A/zh active Pending
- 2016-02-15 BR BR112017017396A patent/BR112017017396A2/pt not_active Application Discontinuation
- 2016-02-15 CU CUP2017000105A patent/CU20170105A7/xx unknown
- 2016-02-15 UA UAA201708102A patent/UA118315C2/uk unknown
- 2016-02-15 EA EA201791563A patent/EA031895B1/ru not_active IP Right Cessation
- 2016-02-15 PE PE2017001447A patent/PE20171449A1/es unknown
- 2016-02-15 KR KR1020177026762A patent/KR20170119705A/ko not_active Ceased
- 2016-02-15 WO PCT/IB2016/050803 patent/WO2016135582A1/en not_active Ceased
- 2016-02-15 TN TNP/2017/000357A patent/TN2017000357A1/en unknown
- 2016-02-15 CR CR20170384A patent/CR20170384A/es unknown
- 2016-02-15 MX MX2017010844A patent/MX2017010844A/es unknown
- 2016-02-15 JP JP2017544584A patent/JP6584521B2/ja not_active Expired - Fee Related
- 2016-02-15 EP EP16707209.9A patent/EP3262057B1/en active Active
- 2016-02-15 AU AU2016225133A patent/AU2016225133B2/en not_active Ceased
- 2016-02-15 SG SG11201706050WA patent/SG11201706050WA/en unknown
- 2016-02-15 ES ES16707209T patent/ES2792899T3/es active Active
- 2016-02-17 US US15/045,679 patent/US10428104B2/en active Active
- 2016-02-19 CA CA2921314A patent/CA2921314A1/en not_active Abandoned
- 2016-02-19 TW TW105104968A patent/TWI622595B/zh not_active IP Right Cessation
- 2016-02-22 UY UY0001036564A patent/UY36564A/es not_active Application Discontinuation
-
2017
- 2017-07-24 IL IL253637A patent/IL253637A0/en unknown
- 2017-07-26 ZA ZA2017/05092A patent/ZA201705092B/en unknown
- 2017-07-28 NI NI201700095A patent/NI201700095A/es unknown
- 2017-08-08 PH PH12017501413A patent/PH12017501413A1/en unknown
- 2017-08-14 SV SV2017005514A patent/SV2017005514A/es unknown
- 2017-08-17 CO CONC2017/0008403A patent/CO2017008403A2/es unknown
- 2017-08-21 DO DO2017000195A patent/DOP2017000195A/es unknown
- 2017-08-24 GT GT201700189A patent/GT201700189A/es unknown
- 2017-08-24 CL CL2017002155A patent/CL2017002155A1/es unknown
-
2018
- 2018-12-11 AU AU2018278842A patent/AU2018278842A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492348B1 (en) * | 1998-06-23 | 2002-12-10 | Smithkline Beecham Corporation | Adenosine derivatives |
| US20040043960A1 (en) * | 2002-08-15 | 2004-03-04 | Jeff Zablocki | Partial and full agonists of A1 adenosine receptors |
Non-Patent Citations (6)
| Title |
|---|
| Kanchan Devkota et al., Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2, ACS Medicinal chemistry letters, vol.5, 2014, pp.293-297 |
| Kung PP et al., Design, synthesis, and biological evaluation of novel human 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) substrates, Bioorganic & Medicinal Chemistry Letters, vol.15, 2005, pp.2829-2833 |
| Müller CE et al., Recent developments in adenosine receptor ligands and their potential as novel drugs, Biochim Biophys Acta, vol.1808, 2010, pp.1290-1308 |
| Müller CE et al., Recent developments in adenosine receptor ligands and their potential as novel drugs, Biochim Biophys Acta, vol.1808, 2010, pp.1290-1308 Kanchan Devkota et al., Analogues of the Natural Product Sinefungin as Inhibitors of EHMT1 and EHMT2, ACS Medicinal chemistry letters, vol.5, 2014, pp.293-297 Ritesh Kumar et al., Activation and inhibition of DNA methyltransferases by S-adenosyl-l-homocysteine analogues, Bioorganic & Medicinal Chemistry, vol.16, 2008, pp.2276-2285 Kung PP et al., Design, synthesis, and biological evaluation of novel human 5'-deoxy-5'-methylthioadenosine phosphorylase (MTAP) substrates, Bioorganic & Medicinal Chemistry Letters, vol.15, 2005, pp.2829-2833 Tilburg EW et al., 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors, J. Med. Chem., vol.44, 2001, pp.2966-2975 * |
| Ritesh Kumar et al., Activation and inhibition of DNA methyltransferases by S-adenosyl-l-homocysteine analogues, Bioorganic & Medicinal Chemistry, vol.16, 2008, pp.2276-2285 |
| Tilburg EW et al., 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors, J. Med. Chem., vol.44, 2001, pp.2966-2975 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI622595B (zh) | 充當抗癌劑的經取代核苷衍生物 | |
| CN109890797B (zh) | 可用作抗癌剂的取代的碳核苷衍生物 | |
| JP2021512131A (ja) | 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体 | |
| TWI672304B (zh) | 作爲酪胺酸激酶抑制劑之經取代的乙炔基雜雙環化合物 | |
| EA034119B1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| CN104854108A (zh) | 作为pi3k抑制剂的吡咯并三嗪酮 | |
| TW200526639A (en) | Pyrazole derivatives and uses thereof | |
| EP4667458A1 (en) | Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| CN108191837A (zh) | PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用 | |
| KR102386403B1 (ko) | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 | |
| WO2021197467A1 (zh) | 多靶点的抗肿瘤化合物及其制备方法和应用 | |
| HK1241886A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| CN113087724B (zh) | 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途 | |
| OA18433A (en) | Substituted nucleoside derivatives useful as anticancer agents | |
| WO2016204135A1 (ja) | ５員ヘテロ環誘導体 | |
| TW202128707A (zh) | 稠合四環類衍生物、其製備方法及其在醫藥上的應用 | |
| HK40008995A (en) | Substituted carbonucleoside derivatives useful as anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |